Talimogene laherparepvec

Drug Profile

Talimogene laherparepvec

Alternative Names: Herpes simplex virus type 1 GM CSF vaccine; IMLYGIC; JS1/34.5- /47-/GM-CSF; JS1/34.5- /47-/GM-CSF vaccine; OncoVEXGM-CSF; T-VEC

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator BioVex
  • Developer Amgen; BioVex; H. Lee Moffitt Cancer Center and Research Institute; M. D. Anderson Cancer Center; Merck & Co; University of Iowa
  • Class Gene therapies; Oncolytic viruses
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase II Breast cancer; Soft tissue sarcoma
  • Phase I Head and neck cancer; Liver cancer
  • No development reported Pancreatic cancer; Solid tumours

Most Recent Events

  • 22 Mar 2017 Phase-I/II clinical trials in Breast cancer (Neoadjuvant therapy) in USA (Intratumoural) (NCT02779855)
  • 06 Mar 2017 Phase-I clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease) in Japan (Intratumoural) (NCT03064763)
  • 01 Mar 2017 Phase-II clinical trials in Soft tissue sarcoma (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (Intratumoural) (NCT03069378)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top